Lilly stomach cancer drug posts improved survival data; Merck touts new osteoporosis data on odanacatib; Promedior boosts D round;

Conversation on Twitter :

 @FierceBiotech: How should India regulate its clinical trial industry? More | Follow @FierceBiotech

 @JohnCFierce: Zounds! Sloan-Kettering won't use Zaltrap (Sanofi/Regeneron) based on its cost and efficacy. Influential. More | Follow @JohnCFierce

 @RyanMFierce: New website crowdsources cancer therapies (some ideas more useful than others). More | Follow @RyanMFierce

> Eli Lilly ($LLY) got a big vote of confidence from Leerink Swann today after the pharma giant boasted of positive survival results among stomach cancer patients taking ramucirumab in a Phase III study. Leerink Swann sees an 80% chance of approval for a drug that could generate up to $600 million in annual sales. Lilly didn't detail the data on survival, though. Report

> Promedior brought its D round to $24.5 million with the addition of a $3 million investment from Shire Strategic Investment Group. Story

> Merck ($MRK) touted new data on its blockbuster osteoporosis drug hopeful odanacatib, demonstrating it improved mineral density in post-menopausal women.  Story

> Lexicon Pharmaceuticals ($LXRX) saw its share price jump on Friday after reporting that its bowel disorder drug met the goals outlined in a study of gastrointestinal cancer patients.  Report

> The FDA has accepted Depomed's application for Serada, a new treatment for hot flashes. Story

Pharma News

@FiercePharma: Profile of one man who's shaking up India's patent-protected drugmakers: Cipla founder YK Hamied. More | Follow @FiercePharma

> Izvestia: Abbott engineers Russian vaccines buyout. Story

> Top U.S. hospital won't use pricey Sanofi cancer drug. Article

> Cinven builds up Mercury with Amdipharm buy. Report

Medical Device News

 @FierceMedDev: Heart stent surgeries in China are now second only to the U.S., but more than half may be unnecessary. More | Follow @FierceMedDev

 @MarkHFierce: BSX CEO explains its repositioning is an attempt, in part, to respond to a rapidly changing healthcare industry. More | Follow @MarkHFierce

 @DamianFierce: Will GSK's new transparency pledge be a boon for CROs and drug developers? More | Follow @DamianFierce

> Medtronic, St. Jude Medical pursue diversity as MN mulls same-sex marriage ban. Item

> BD, Lab21 team up for cancer diagnostics. Story

Biotech IT News

> Australia goes online for clinical trials awareness. Report

> Fight against 'unwarranted' drug patents goes online. More

> GSK to open clinical data vaults to scientists via website. Story

> Pharma group taps software to track adverse events in mobile apps. Article

CRO News

> How should India regulate its clinical trial industry? Item

> AstraZeneca taps China's Pharmaron to speed R&D. Report

> GSK's transparency pledge could be a boon to drug researchers. News

> Recipharm teams with Astimex on CDMO deal. Story

> Novasep pours $39M into new API plant. Article

And Finally… A year after having neural stem cells transplanted into the brains of four patients with a rare brain disease, investigators say they have demonstrated improved brain function after the therapy boosted levels of myelin. Story

 

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.